Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uveal Melanoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Melanoma 1Gastrointestinal Stromal Tumors 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

spartalizumab 1STA 9090 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disorders of Sex Development × STA 9090 × Clear all
NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡